HLA-DRB1 and melanoma: Based on this result we screened PBMC from six HLA-DRB1*03+ melanoma patients (GA, ME, PK, VHP, SA, BH) and four HLA-DRB1*0301+ healthy donors (BF1, BF3, BF4, BF5) for the presence of peptide #19-reactive T cells.